1.
Nanobodies: natural single-domain antibodies
by Muyldermans, Serge
Annual review of biochemistry, 2013, Vol.82 (1), p.775-797
2.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
by Chen, Rita E
Nature medicine, 2021-04, Vol.27 (4), p.717-726
3.
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
by SHEN, Ben-Quan
Nature biotechnology, 2012, Vol.30 (2), p.184-189
4.
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
by van Schie, K A
Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.311-314
5.
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo
by DiLillo, David J
Nature medicine, 2014-02, Vol.20 (2), p.143-151
6.
A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection
by Gautam, Rajeev
Nature medicine, 2018-05, Vol.24 (5), p.610-616
7.
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies
by Leborgne, Christian
Nature Medicine, 2020-07, Vol.26 (7), p.1096-1101
8.
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
by van Schouwenburg, Pauline A
Annals of the rheumatic diseases, 2013-01, Vol.72 (1), p.104-109
9.
Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications
by Sparrow, Erin
Vaccine, 2016, Vol.34 (45), p.5442-5448
10.
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
by Wilson, Patrick C
Nature, 2008-05-29, Vol.453 (7195), p.667-671
11.
Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice
by Reber, Laurent L., PhD
Journal of allergy and clinical immunology, 2013, Vol.132 (4), p.881-888.e11
12.
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor
by Dussupt, Vincent
Nature medicine, 2020-02, Vol.26 (2), p.228-235
13.
Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission
by WATKINS, Jennifer D
AIDS (London), 2013, Vol.27 (9), p.F13-F20
14.
A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
by Garcês, Sandra
Annals of the rheumatic diseases, 2014-06, Vol.73 (6), p.1138-1143
15.
Antibodies Against Neutralization Epitopes of Human Cytomegalovirus gH/gL/pUL128-130-131 Complex and Virus Spreading May Correlate with Virus Control In Vivo
by Lilleri, Daniele
Journal of clinical immunology, 2012-07-27, Vol.32 (6), p.1324-1331
16.
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
by Xu, Kai
Nature medicine, 2018-06, Vol.24 (6), p.857-867
17.
Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1 and B3) in Iran
by Fatemi Nasab, Ghazal Sadat
Pathogens and disease, 2016-11-01, Vol.74 (8), p.ftw089
18.
Novel vaccination approach for dengue infection based on recombinant immune complex universal platform
by Kim, Mi-Young
Vaccine, 2015, Vol.33 (15), p.1830-1838
19.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
by Ehrhardt, Stefanie A
Nature medicine, 2019-10, Vol.25 (10), p.1589-1600
20.
Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity
by Yamanaka, Atsushi
Vaccine, 2016, Vol.34 (51), p.6449-6457
